Actively Recruiting
Evaluating Oral Acamprosate for Safety and Clinical Effects in Adults with ALS and C9orf72 Mutation
Led by National Institute of Neurological Disorders and Stroke (NINDS) · Updated on 2026-10-01
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying amyotrophic lateral sclerosis ALS, a condition that damages nerve cells in the brain and spinal cord, leading to muscle weakness and loss of movement. This trial focuses on people with ALS who have a mutation in the C9orf72 gene. The study aims to evaluate the safety and clinical effects of the drug acamprosate in this group, exploring its potential impact on disease progression. Participants will take acamprosate tablets by mouth, with a dose of 2 pills three times daily during meals for 24 weeks. The study involves 13 visits over 32 weeks, including five clinic visits and eight phone visits. Baseline assessments include physical exams, blood tests, imaging scans, breathing tests, neurological exams, cognitive and behavioral assessments, and lumbar puncture. These tests will be repeated during follow-up visits. Throughout the study, participants will record their medication doses and missed doses in a diary, which will be reviewed during phone calls. Researchers will monitor safety by tracking adverse events and lab results. They will also assess changes in ALS functional status, disease severity, quality of life, biomarkers, and imaging measures. The total participation duration is approximately 32 weeks with ongoing assessments during clinic and phone visits.
CONDITIONS
Brief Title
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
Research Team
C
Carol H Hoffman
J
Justin Y Kwan, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here